# Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm

> **NCT01691313** · PHASE2 · COMPLETED · sponsor: **Laguna Pharmaceuticals, Inc.** · enrollment: 104 (actual)

## Conditions studied

- Symptomatic Atrial Fibrillation
- Atrial Flutter

## Interventions

- **DRUG:** Vanoxerine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01691313
- **Lead sponsor:** Laguna Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-09
- **Final completion:** 2013-10
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2015-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01691313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01691313, "Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01691313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*